These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30458929)

  • 1. Intellectual Property in the Field of Regenerative Medicine in Japan.
    Asano S; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1823-1827. PubMed ID: 30458929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Toxicity Studies for Regenerative Medicine in Japan.
    Shigeto J; Ichiki T; Nii T; Konno K; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1813-1822. PubMed ID: 30458928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intellectual property strategy for regenerative medicine: is it time to 'regenerate'?
    Komatani TS
    Pharm Pat Anal; 2014 Sep; 3(5):475-9. PubMed ID: 25374315
    [No Abstract]   [Full Text] [Related]  

  • 4. Upcoming challenges in intellectual property presented by emerging pharmaceutical technologies.
    Komatani TS
    Pharm Pat Anal; 2017 Jan; 6(1):1-4. PubMed ID: 28198642
    [No Abstract]   [Full Text] [Related]  

  • 5. Japan's patent issues relating to life science therapeutic inventions.
    Tessensohn JA
    Expert Opin Ther Pat; 2014 Sep; 24(9):953-7. PubMed ID: 25089628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of the National Consortium for Regenerative Medicine and National Regenerative Medicine Database in Japan.
    Okada K; Sato Y; Sugiyama D; Sawa Y
    Clin Ther; 2018 Jul; 40(7):1076-1083. PubMed ID: 29958729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring innovation in stem cell and regenerative medicine in Japan: the power of the consortium-based approach.
    Munisi HI; Xie Z; Sengoku S
    Regen Med; 2014; 9(4):467-77. PubMed ID: 25159064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory perspectives of Japan.
    Kusakabe T
    Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intellectual property in entomology: Analysis and perspective on recent trends in global patent publications.
    Hamm RL; Gregg A; Sparks TC
    Pest Manag Sci; 2020 May; 76(5):1603-1611. PubMed ID: 32034856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoting justice in stem cell intellectual property.
    Regenberg A; Mathews DJ
    Regen Med; 2011 Nov; 6(6 Suppl):79-84. PubMed ID: 21999266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patent and intellectual property rights related to pharmaceuticals: global future perspectives: Japan.
    Komatani TS
    Pharm Pat Anal; 2016 Jul; 5(4):227-35. PubMed ID: 27334256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cells: intellectual property issues in regenerative medicine.
    Zachariades NA
    Stem Cells Dev; 2013 Dec; 22 Suppl 1(Suppl 1):59-62. PubMed ID: 24304078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan.
    Okada K; Miyata T; Sawa Y
    Regen Med; 2017 Mar; 12(2):179-186. PubMed ID: 28244828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Regenerative Medicine Stakeholders Adapt to Ever-Changing Technology and Regulatory Challenges? Snapshots from the World TERMIS Industry Symposium (September 10, 2015, Boston).
    Bayon Y; Van Dyke M; Buelher R; Tubo R; Bertram T; Malfroy-Camine B; Rathman M; Ronfard V
    Tissue Eng Part B Rev; 2017 Apr; 23(2):159-162. PubMed ID: 27771996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent portfolio management: literature review and a proposed model.
    Conegundes De Jesus CK; Salerno MS
    Expert Opin Ther Pat; 2018 Jun; 28(6):505-516. PubMed ID: 29718747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of Global Trend on Biomedical Application of Polyhydroxyalkanoate (PHA): A Patent Survey.
    Paulraj P; Vnootheni N; Chandramohan M; Thevarkattil MJP
    Recent Pat Biotechnol; 2018; 12(3):186-199. PubMed ID: 29384069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Social Framework Surrounding the Development of Regenerative Medicine in Japan.
    Nakazawa E; Takimoto Y; Akabayashi A
    Camb Q Healthc Ethics; 2016 Jul; 25(3):466-71. PubMed ID: 27348830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
    Inokuma Y
    Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can regenerative medicine save Big Pharma’s business model from the patent cliff?
    Denoon A; Vollebregt E
    Regen Med; 2010 Sep; 5(5):687-90. PubMed ID: 20868323
    [No Abstract]   [Full Text] [Related]  

  • 20. Herbal Technological Prospects of
    Alves LP; Dos Santos WM; de Souza ML; Rolim LA; Rolim-Neto PJ
    Recent Pat Biotechnol; 2024; 18(3):241-256. PubMed ID: 37605394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.